Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component

Roberto Moretto, Federica Morano, Elena Ongaro, Daniele Rossini, Filippo Pietrantonio, Mariaelena Casagrande, Carlotta Antoniotti, Salvatore Corallo, Federica Marmorino, Francesco Cortiula, Federico Nichetti, Beatrice Borelli, Gemma Zucchelli, Alessandra Boccaccino, Gianluca Masi, Filippo de Braud, Alfredo Falcone, Chiara Cremolini

Research output: Contribution to journalArticlepeer-review

Abstract

Adenocarcinoma with mucinous histology or mucinous component are histologic subtypes of metastatic colorectal cancers (mCRCs) with limited benefit from cytotoxic agents. Their sensitivity to anti-epithelial growth factor receptors (EGFRs) is not clear. We retrospectively identified patients with RAS/BRAF wild-type mCRC treated with anti-EGFRs. Our findings suggest no benefit from anti-EGFRs in mCRC with mucinous histology or mucinous component, irrespective of sidedness.

Original languageEnglish
Pages (from-to)116-124
Number of pages9
JournalClinical Colorectal Cancer
Volume18
Issue number2
DOIs
Publication statusPublished - Jun 2019

Keywords

  • Adenocarcinoma with mucinous component
  • Anti-EGFR monoclonal antibodies
  • Metastatic colorectal cancer
  • Mucinous adenocarcinoma
  • RAS and BRAF wild-type mCRC

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Fingerprint

Dive into the research topics of 'Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component'. Together they form a unique fingerprint.

Cite this